Fresenius Misses Q2 Earnings Estimates - Analyst Blog
July 31 2013 - 12:00PM
Zacks
Dialysis company Fresenius
Medical Care (FMS) announced second quarter 2013 adjusted
earnings of 44 cents per American Depositary Share (ADS), which was
lower than the Zacks Consensus Estimate of 46 cents per ADS.
Adjusted earnings exclude one-time items such as
acquisition-related expenses associated with the buyout of Liberty
Dialysis Holdings and impact from sequestration implemented from
Apr 2013. Adjusted earnings remained flat year over year.
Net income attributable to the company dropped 9% year over year to
$263 million in the quarter.
Quarter in Detail
Net revenue grew 5% (up 6% in terms of constant currency) year over
year to $3,613 million in the reported quarter. Revenues marginally
missed the Zacks Consensus Estimate of $3,615 million. Organic
sales growth was 5% on a global basis.
On a geographic basis, revenues from the North American markets
rose 6% to $2,375 million in the quarter while overseas revenues
increased 5% (up 6% in terms of constant currency) to $1,228
million.
Dialysis services revenues increased 5% (up 6% in terms of constant
currency) year over year to $2,743 million with U.S. sales spurting
6% year over year to $2,157 million and international sales
ascending 4% (up 7% in terms of constant currency) year over year
to $586 million.
Consolidated dialysis product revenues increased 6% (up 5% in terms
of constant currency) year over year to $870 million. Dialysis
product sales in the U.S. market rose 6% to $218 million.
International dialysis product sales increased 5% (up 5% in terms
of constant currency) to $642 million.
Operating Statistics
Fresenius operated a network of 3,212 dialysis clinics (up 3% year
over year) across North America and overseas markets, as of Jun 30,
2013. The number of clinics in North America and offshore dialysis
clinics both increased 3% year over year.
Fresenius provided dialysis treatment to 264,290 patients (up 3%
year over year) on a global scale, as of Jun 30, 2013. Patients in
North America increased 3% whereas number of patients in
international markets increased 4% year over year.
The company provided 19.7 million dialysis treatments (up 5% year
over year) globally, as of Jun 30, 2013. Fresenius’ North American
franchise rose 5% while the international segment improved 3% year
over year.
Margins
Operating margin dropped to 15.1% from 17.2% in the prior year
quarter. In North America, operating margin was lower at 10.9% from
12.6% a year ago while operating margin for overseas markets
decreased to 5.8% from 6.0% in the year-ago period. On an adjusted
basis, operating margin was 15.4%, down from 16.6% in the prior
year quarter.
Balance Sheet
Fresenius concluded the second quarter with cash from operations of
$525 million (14.5% of sales), representing an increase of 16% year
over year.
The company spent $173 million on capital expenditure in the
quarter. Free cash flow, prior to acquisitions, was $352 million
versus $300 million a year ago. The company spent $13 million on
acquisitions and investments, net of divestitures. Free cash flow,
post acquisitions, divestitures and investments, was $339 million
compared with $306 million in the prior-year period.
Fresenius initiated a share repurchase program on May 20, 2013,
which is expected to end in the third quarter of 2013. The board
has authorized to buy back up to $500 million of its common stock.
As of Jun 30, 2013, the company repurchased 3.58 million shares
worth $249 million.
Guidance
Fresenius reaffirmed its revenue forecast for 2013. The company
envisions sales of over $14,600 million for 2013, up 6% year over
year. It raised the upper end of its net income guidance (for
shareholders) for 2013 to $1,100-$1,500 million from $1,100-$1,200
million. The company expects capital expenditure of roughly $700
million and plans to spend around $500 million (earlier $300
million) on acquisitions. The guidance assumes the impact from
sequestration.
Our Take
We are disappointed with Fresenius’ second quarter results, which
missed the Zacks Consensus Estimate on both fronts. Moderate sales
growth was dampened by declining margins. Macroeconomic issues such
as a budget cut in the U.S. (sequestration) is likely to add more
pressure on the company’s margins.
The company’s principal competitor in the U.S. is DaVita
HealthCare Partners (DVA), which provides dialysis
services for patients suffering from chronic kidney failure or end
stage renal disease. Fresenius also competes with Baxter
International (BAX).
The stock carries a Zacks Rank #4 (Sell). Right now, IDEXX
Laboratories (IDXX) looks attractive with a Zacks Rank #2
(Buy).
BAXTER INTL (BAX): Free Stock Analysis Report
DAVITA INC (DVA): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis Report
IDEXX LABS INC (IDXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
DaVita (NYSE:DVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Oct 2023 to Oct 2024